title: After first-line ART: towards an evidence-based SECOND-LINE.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, 20900 Monza, Italy. a.soria@hsgerardo.org
authors.forename: Alessandro
authors.initials: A
authors.lastname: Soria
authors.forename: Andrea
authors.initials: A
authors.lastname: Gori
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage*; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage*; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D019438:Ritonavir / Q000008:administration & dosage*
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D000068898:Raltegravir Potassium; D019438:Ritonavir